On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.
What is the Objective of this Poster?
- Results provide insights into real-world treatment patterns for HS within a diverse set of US healthcare settings.
- Adalimumab use has increased steadily since the Food and Drug Administration approval for the treatment of HS, while incision/drainage procedures and laser surgeries have both seen steady declines.
- As new treatments are developed and introduced, further analyses would be helpful to understand uptake of therapies and prescription patterns among HS patients.
Register to view this poster now!